Sustiva
Sustiva

5.31
For patients managing HIV and viral conditions, this generic medicine blocks viral replication to lower the overall infectious load in the body.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Efavirenz
Reference Brand
Efavirenz
Product Origin
Generic Alternative
Reference Manufacturer
Bristol-Myers Squibb
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Antivirals, Antivirals
Product Category
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Pharmacological Class
NNRTI
Manufacturer Description
Intended to relieve retroviral multiplication to support immune lymphocyte preservation and target reverse transcriptase.
Mechanism of Action
Non-competitively inhibits HIV-1 reverse transcriptase, halting viral replication inside host cells.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours
Contraindications
Concurrent use of highly CYP3A4-dependent medications, Severe hepatic impairment
Severe Adverse Events
Severe depression and suicidal ideation — requires immediate medical attention, Severe hepatotoxicity — requires immediate medical attention
Common Side Effects
Dizziness, Headache, Insomnia
Uncommon Side Effects
Vivid dreams, Rash, Fatigue
Drug Interactions
Rifampin, Simvastatin, St. John's Wort
Pregnancy Safety Warnings
TGA Category D: Potential risk of neural tube defects. Avoid in first trimester. Breastfeeding: Not recommended.
Age Restrictions
Approved for children over three months and adults.
Storage Guidelines
Store below 25°C.
Related Products
Information related to Sustiva is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
where to access Immune Suppressants - Salazopyrin Price